Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Short Interest Up 498.6% in February

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) was the target of a significant increase in short interest in February. As of February 28th, there was short interest totalling 43,100 shares, an increase of 498.6% from the February 13th total of 7,200 shares. Based on an average trading volume of 196,400 shares, the short-interest ratio is presently 0.2 days. Approximately 0.0% of the company’s shares are sold short.

Chugai Pharmaceutical Stock Performance

Shares of CHGCY traded up $0.48 during trading hours on Wednesday, hitting $22.90. The company had a trading volume of 93,611 shares, compared to its average volume of 193,079. The stock has a market capitalization of $75.36 billion, a price-to-earnings ratio of 29.74 and a beta of 0.77. The firm has a fifty day moving average price of $22.73 and a 200-day moving average price of $22.99. Chugai Pharmaceutical has a 52-week low of $14.52 and a 52-week high of $27.19.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its earnings results on Thursday, January 30th. The company reported $0.18 EPS for the quarter. Chugai Pharmaceutical had a return on equity of 21.53% and a net margin of 33.07%. Research analysts anticipate that Chugai Pharmaceutical will post 0.74 earnings per share for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.